Pharmaceutical

Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy

New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathwayWHITE PLAINS, N.Y., Aug. 20,…

4 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative…

4 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar…

4 months ago

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Sai Life Sciences HYDERABAD, India, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306…

4 months ago

337,000 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at…

4 months ago

Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution

Louvain-La-Neuve, Belgium, August 20, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and…

4 months ago

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

4 months ago

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Investment to support NovaBay’s continued public listing and provide funding for a future strategic transactionEMERYVILLE, Calif., Aug. 19, 2025 (GLOBE…

4 months ago

Scientific Industries Reports Financial Results for Second Quarter of Fiscal Year 2025

TORBAL DIVISION SALES UP 11%SECURED $10 MILLION IN STRATEGIC DIVESTURE OF GENIE PRODUCT LINEVIVID AND BIOPROCESSING NEW PRODUCT AI ROADMAP…

4 months ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient…

4 months ago